1. Home
  2. ZYME

as of 11-28-2025 12:39pm EST

$26.58
$0.75
-2.74%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Chart Type:
Time Range:
Founded: 2003 Country:
United States
United States
Employees: N/A City: MIDDLETOWN
Market Cap: 1.2B IPO Year: 2017
Target Price: $28.00 AVG Volume (30 days): 1.9M
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.84 EPS Growth: N/A
52 Week Low/High: $9.03 - $28.49 Next Earning Date: 11-06-2025
Revenue: $134,481,000 Revenue Growth: 116.21%
Revenue Growth (this year): 65.21% Revenue Growth (next year): 20.39%

AI-Powered ZYME Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 76.55%
76.55%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Zymeworks Inc. News

ZYME Breaking Stock News: Dive into ZYME Ticker-Specific Updates for Smart Investing

All ZYME News

Share on Social Networks: